RGCC International

RGCC International RGCC is a specialist medical genetics company, established in 2004 with headquarters in Switzerland.

At RGCC, we are at the forefront of revolutionizing healthcare through personalized solutions for cancer and chronic diseases.​

Our commitment is global, aiming to provide personalised, diagnostic and therapeutic options to patients worldwide.​ We are experts in developing and providing personalised cancer genetics tests for doctors and patients, and testing tumours for sensitivity and resistance to chemotherapy treatment and a range of natural substances. We are actively involved in pharmaceutical research and development. Our facilities are equipped with the most technologically advanced equipment and specialised software for data analysis. RGCC is a global organisation, and we work in collaboration with branch offices and distributors to provide a worldwide service.

On International Women’s Day 2026, we celebrate the women whose expertise, leadership, and dedication drive progress in ...
08/03/2026

On International Women’s Day 2026, we celebrate the women whose expertise, leadership, and dedication drive progress in worldwide.

At Central Europe in Halle (Saale), women represent more than 80% of our team: scientists, team members, and leaders shaping the future of oncology and precision medicine.

Today, we honor the journeys, ambition, and impact of the women advancing research and improving patient care worldwide.

Every patient journey is unique, and so is the care they deserve.P.W.’s testimonial reflects our commitment to combining...
05/03/2026

Every patient journey is unique, and so is the care they deserve.

P.W.’s testimonial reflects our commitment to combining advanced diagnostics with compassionate, patient-centered care, supporting informed treatment decisions at every step.

🌱 Read more patient stories: rgcc-international.com/testimonials/

March is Colorectal   Awareness Month.According to the World Health Organization (WHO), colorectal cancer is the third m...
02/03/2026

March is Colorectal Awareness Month.

According to the World Health Organization (WHO), colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related deaths.

Awareness, prevention, and early detection matter. Healthy lifestyle choices, such as staying active, eating more fruits and vegetables, limiting processed meats, and avoiding smoking and excessive alcohol, can help reduce risk.

🎗️ Let’s raise awareness and encourage prevention.

25/02/2026

Our Oncotrace test is a powerful monitoring tool designed to assess cancer progression. Through a simple blood draw, Oncotrace detects and analyzes circulating tumor cells ( ), evaluating their presence, enumeration, and immunophenotype. This information helps determine how advanced the cancer is and the potential for metastatic spread.

🎥 Watch the video to hear what our practitioners say about .

Have you read the real-world study?A real-world study shows that circulating tumor cell (CTC) analysis can guide persona...
19/02/2026

Have you read the real-world study?
A real-world study shows that circulating tumor cell (CTC) analysis can guide personalized treatment and improve outcomes for women with advanced or recurrent ovarian .

The study, “Tailoring treatment for advanced and/or recurrent using the response of circulating tumor cells to therapy: a retrospective analysis,” found that CTC-guided approaches may extend time on treatment and help predict longer survival.

Using data from ’s Onconomics test, physicians were able to tailor therapies based on CTC counts, biomarker expression, chemosensitivity, and mRNA profiling, reinforcing the value of precision diagnostics in cancer care.

🔍 Read it here: rgcc-international.com/news/ovarian-cancer-care/

Shining the spotlight on our sister company, Welmedis!Aiming to transform cancer therapy by developing targeted   therap...
16/02/2026

Shining the spotlight on our sister company, Welmedis!

Aiming to transform cancer therapy by developing targeted therapeutics, Welmedis is dedicated to developing novel medications that target the unique characteristics of each patient’s cancer, offering more effective and tailored therapeutic solutions.

Using gene and protein expression data from the target identification pipeline, Welmedis identifies novel targets for small-molecule therapeutics tailored to specific patient populations. Their innovative approach combines cutting-edge diagnostics and drug development to provide the most effective treatments for specific cancer types.

Learn more about Welmedis >

We deliver personalized cancer treatments powered by diagnostic insights. Discover more about our mission and our cutting-edge work.

The information gained from Immune-Frame enables healthcare professionals to identify potential immune dysregulations or...
12/02/2026

The information gained from Immune-Frame enables healthcare professionals to identify potential immune dysregulations or health risks, guide treatment strategy, and track immune recovery following therapies such as chemotherapy, immunotherapy, or cellular therapy.

👉 Understand your immune system’s health and performance: rgcc-international.com/tests/immune-frame/

RGCC tests offer valuable insights into the most effective treatment options for each patient.Our   panels evaluate how ...
09/02/2026

RGCC tests offer valuable insights into the most effective treatment options for each patient.

Our panels evaluate how different anti-cancer drugs and natural substances target cells uniquely in each individual. Plus, they also include genetic detailing on the cancer cells to let you know how gene expressions and physiological expressions manifest in a cancer patient’s body.

🔗 Learn more >> rgcc-international.com/tests

February 4 marks World Cancer Day, a global initiative dedicated to raising awareness and driving action against  .It is...
04/02/2026

February 4 marks World Cancer Day, a global initiative dedicated to raising awareness and driving action against .

It is an important opportunity to highlight key risk factors and the preventive actions that can help reduce cancer risk, such as limiting to***co use and alcohol consumption, reducing exposure to ultraviolet radiation from the sun, and adopting healthier lifestyle choices.

Today, we stand with the global community to promote prevention, raise awareness, and support efforts toward a healthier future for all.

🎗 Join the global movement for World Cancer Day and learn more: worldcancerday.org

26/01/2026

Dr. Clayton Bell, Functional & Integrative Medicine Physician, shares how he incorporates RGCC testing into his clinical decision-making to help guide personalized treatment approaches.

By using the Onconomics panels, Dr. Bell gains insights that support treatment planning, helping physicians evaluate potential responsiveness to chemotherapy agents, immunotherapies, and hormone-blocking therapies for each individual patient.

Watch the full interview:
📽️ youtube.com/watch?v=98GK0V5OI3U&t=7s

🌍 Cervical   remains a global health challenge, with approximately 660,000 new cases diagnosed worldwide each year, the ...
22/01/2026

🌍 Cervical remains a global health challenge, with approximately 660,000 new cases diagnosed worldwide each year, the majority occurring in middle- and low-income regions. These disparities largely reflect unequal access to vaccination (one of the main risk factors for cervical cancer), cervical screening, timely treatment, and broader social and economic determinants of health.

Expanding access to prevention and early detection has the potential to significantly reduce incidence and save lives.

🔗 Learn more about and treatment options: https://rgcc-international.com/patient-information/cervical-cancer-treatment/

Circulating Tumor Cells (CTCs) are a key indicator of active   in the body. Monitoring the CTC levels helps clinicians a...
19/01/2026

Circulating Tumor Cells (CTCs) are a key indicator of active in the body. Monitoring the CTC levels helps clinicians assess disease progression and evaluate treatment response.
A high CTC count may indicate an increased risk of recurrence, making regular CTC testing an essential part of managing cancer treatment.

👉 Learn more about tests >> https://rgcc-international.com/research-and-development/

Adresse

Baarerstrasse 95
Zug
6300

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von RGCC International erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Teilen

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram